Emergent BioSolutions Inc. secured approval to sell its typhoid fever vaccine in five additional European Union member states — France, Portugal, Poland, Czech Republic and Slovakia.

The company's Vivotif oral vaccine is used to prevent typhoid fever, a potentially severe and life-threatening infection caused by the bacterium Salmonella enterica serovar Typhi, in adults and children aged 5 and older.

The Gaithersburg, Md.-based biotech company is selling the drug under the name Vivotif in the U.S. and Europe and as Typhoral L in Germany.